Viridian Therapeutics, Inc.\DE 4

Viridian Therapeutics CMO Radhika Tripuraneni exercised options for 40,000 shares of common stock at $13.21 per share on August 14, 2026.

On August 14, 2026, Viridian Therapeutics, Inc. Chief Medical Officer Radhika Tripuraneni exercised stock options covering 40,000 shares of common stock at an exercise price of $13.21 per share, acquiring 40,000 shares of common stock with an implied transaction value of approximately $528,400. The corresponding option award for 40,000 shares, which was already fully vested and carried the same $13.21 exercise price, was reduced by 40,000 shares to zero following the exercise, indicating the option grant was fully exercised. After the transaction, the reporting person directly held 40,000 shares of Viridian common stock. No open-market purchase or sale occurred; the transaction reflects an option exercise and conversion into common stock as part of equity compensation.

Filing Facts

CIK

1590750

Ticker

VRDN

Form

4

Source Type

fda

Accession

0001193125-26-355735

Alert Tier

5